Interim report of MEDICLIN Aktiengesellschaft

for the period from 1 January 2024 to 30 September 2024

MEDICLIN: Key data on business development

	9M 2023	9M 2022
Number of shares in millions	47.5	47.5
Number of cases (inpatient)	81,685	78,495
Number of beds as of 30.09.	8,132	8,315
Occupancy rate in %	84.5	78.5
Number of full-time employees (average number)	7,014	7,014

In thousands of €	9M 2023	9M 2022
Cash flow from operating activities	49,858	34,540
Cash flow from operating activities per share in €	1.05	0.73
Sales	547,136	526,329
EBITDA	68,246	65,183
EBITDA margin in %	12.5	12.4
EBIT (operating result)	29,385	10,088
EBIT margin in %	5.4	1.9
Financial result	–15,944	–5,752
Total consolidated result	15,228	4,439
Earnings per share in €	0.32	0.09
Gross capital expenditure	25,958	17,638
Thereof subsidies	6,373	5,823
Interest coverage factor (EBITDA / interest result)	4.3x	11.3x

In thousands of €	30.09.2024	31.12.2023
Balance sheet total	904,095	880,502
Equity	212,387	196,029
Equity ratio in %	23.5	22.3
Return on equity[1] in %	–5.2	–5.5
Financial liabilities (to banks)	92,030	93,381
Cash and cash equivalents	129,994	115,286
Net financial debt[2]	–4,581	17,217
Net financial debt[2]/ EBITDA[3]	–0.1x	0.3x

[1] Total consolidated result in the last 12 months / equity
[2] Adjusted average net financial debt over the last four quarterly reporting dates (adjusted for liabilities under IFRS 16 and liabilities and cash and cash equivalents from loan subsidies)
[3] Adjusted EBITDA in the last 12 months (adjusted for IFRS 16)

Due to arithmetical reasons, calculation differences of +/– one unit (€, % etc.) may occur; percentage rates and changes in % were calculated on the basis of non-rounded € values.

Interim Group management report of MEDICLIN Aktiengesellschaft

for the period from 1 January 2024 to 30 September 2024

Report on the economic position for the first nine months of 2024

General statement on results of operations, financial position and net assets

Occupancy continues to rise year-on-year

A rising occupancy rate with relation to medical, therapeutic and nursing care services led to sales growth within the Group. In the first nine months of the current financial year, the number of inpatients treated dropped slightly by 0.6 % to 80,983 patients, while the occupancy rate rose by 1.6 percentage points to 86.0 % compared to the prior-year period.

Results of operations

Group sales in the first nine months of 2024 amounted to EUR 558.2 mill., thus exceeding the prior-year figure (EUR 547.1 mill.) by 2.0 % or EUR 11.1 mill. Adjusted for benefits under the protective shield to manage the COVID-19 pandemic and divestments, Group sales even rose by EUR 40.9 mill. or 8.1 % compared to the previous year.

The Group operating result was EUR 34.5 mill. in the period under review and was thus EUR 5.1 mill. higher than the prior-year figure of EUR 29.4 mill. Expenses for raw materials and consumables used dropped by EUR 7.8 mill. year-on-year. The Group's staff costs, in turn, climbed by EUR 6.5 mill. year-on-year.

Financial position and net assets

MEDICLIN's capital expenditure in the first nine months of 2024 totalled EUR 31.4 mill. for tangible and intangible assets (9M 2023: EUR 26.0 mill.). Cash and cash equivalents amounted to EUR 130.0 mill. as of 30 September 2024 (31.12.2023: EUR 115.3 mill.). Cash and cash equivalents still include benefits under the protective shield amounting to EUR 19.6 mill. that will likely have to be repaid in the current year. Furthermore, the cash and cash equivalents item includes EUR 18.2 mill. in subsidies for the planned construction of a new clinic.

The Management Board continues to rate both the results of operations and the Group's financial position and net assets as sound.

Outlook 2024 – Positive business development in the third quarter of 2024

MEDICLIN's business performance was positive in the third quarter of 2024 with regard to occupancy, costs and sales. Given this, the Management Board assumes that the upper end of the EBIT forecast for the current financial year, which had been specified to amount to EUR 33.0-39.0 mill. after the six-months period, will be reached. The forecast for the Group's sales development of –2.0 % and 0.0 % is also expected to be met at the upper end of the range. Assuming that the sector environment remains unchanged, MEDICLIN is thus well on its way to reaching the forecasts for the 2024 financial year.

Results of operation, financial position and net assets

Results of operation

Group sales in the first nine months of 2024 were up on the previous year's value, increasing by EUR 11.1 mill. or 2.0 %, respectively.

SALES AND EARNINGS PERFORMANCE OF THE GROUP

	9M 2024	9M 2023
Group sales in millions of €	558.2	547.1
Raw materials and consumables used in millions of €	96.5	104.3
Cost of materials ratio in %	17.3	19.1
Staff costs in millions of €	353.7	347.2
Staff costs ratio in %	63.4	63.5
Depreciation and amortisation in millions of €	37.1	38.9
Other operating expenses in millions of €	51.8	49.5
Group operating result in millions of €	34.5	29.4

Compared to the comparable prior-year period, the expenses for raw materials and consumables used decreased by EUR 7.8 mill. (–7.5 %) to EUR 96.5 mill. The expenses for raw materials and supplies accounted for EUR 4.0 mill. of this decrease, while expenses for purchased services contributed EUR 3.7 mill. In the raw materials and supplies item, the expenses for medical supplies (EUR –3.1 mill.) as well as the expenses for implants (EUR –2.1 mill.) were reduced on the prior-year period, while food expenses continued to increase (EUR +1.0 mill.). The cost of external medical staff accounted for the largest decline of EUR 4.4 mill. in the cost of purchased services item, dropping to EUR 6.6 mill. in the period under review. This positive effect was counteracted by the rise in energy costs by EUR 1.1 mill. to EUR 13.0 mill.

Depreciation and amortisation decreased by EUR 1.7 mill. (–4.4 %). The financial result of EUR –16.1 mill. was EUR 0.7 mill. below the previous year's level (9M 2023: EUR –15.9 mill.).

The Group operating result improved by EUR 5.1 mill. to EUR 34.5 mill.

The total consolidated result attributable to shareholders of MEDICLIN Aktiengesellschaft was EUR 14.9 mill. (9M 2023: EUR 15.3 mill.). Earnings per share came to EUR 0.31 (9M 2023: EUR 0.32).

The sales and earnings performance at segment level is illustrated in detail in the segment reporting section.

Financial position and net assets

The cash flow from operating activities of EUR 59.5 mill. clearly exceeded the prior-year level of EUR 49.9 mill. in the first nine months of 2024. Payments received from investment subsidies totalled EUR 11.4 mill. (9M 2023: EUR 17.8 mill.). MEDICLIN expended a total of EUR 30.2 mill. on tangible and intangible assets (9M 2023: EUR 24.9 mill.). Adjusted for proceeds from divestments amounting to EUR 9.5 mill., the cash flow from investing activities amounted to EUR –8.5 mill., down from EUR 2.5 mill. in the previous year. The cash flow from financing activities amounted to EUR –36.3 mill., following EUR –34.1 mill. in the prior-year period.

All in all, the cash flow for the period is EUR 14.7 mill. (9M 2023: EUR 17.4 mill.), taking cash and cash equivalents at the end of the period up to EUR 130.0 mill. which is above the prior year level (30.09.2023: EUR 109.6 mill.). Cash and cash equivalents still include benefits under the protective shield amounting to EUR 19.6 mill. that will likely have to be repaid in the current year.

LIQUIDITY

In millions of €	9M 2024	9M 2023
Cash flow from operating activities	59.5	49.9
Thereof total consolidated result	15.0	15.2
Cash flow from investing activities	–8.5	2.5
Cash flow from financing activities	–36.3	–34.1
Change in consolidation scopes for financial funds	0.0	–0.9
Cash flow for the period	**14.7**	**17.4**
Cash and cash equivalents at the beginning of the period	115.3	92.2
Cash and cash equivalents at the end of the period	**130.0**	**109.6**

There was no significant change in net assets as of the balance sheet date on 30 September 2024 compared to 31 December 2023.

BALANCE SHEET STRUCTURE

In millions of €	30.09.2024	In % of balance sheet total	31.12.2023	In % of balance sheet total
Assets				
Non-current assets	584.8	64.7	580.7	66.0
Current assets	319.3	35.3	299.8	34.0
	904.1	**100.0**	**880.5**	**100.0**
Equity and liabilities				
Equity	212.4	23.5	196.0	22.3
Non-current liabilities	507.9	56.2	513.2	58.3
Current liabilities	183.8	20.3	171.3	19.4
	904.1	**100.0**	**880.5**	**100.0**

Segment reporting

In the post-acute segment, sales rose by EUR 24.2 mill. or 7.2 % to EUR 361.2 mill. (9M 2023: EUR 337.0 mill.). The current financial year figures do not include any benefits under the protective shield to manage COVID-19 worth mentioning (9M 2023: EUR 4.5 mill.). Adjusted for this effect, segment sales rose by EUR 28.7 mill. or 8.6 %, respectively.

The acute segment posted a decline in segment sales of EUR 16.3 mill. or 8.5 %. This is due to the sale of the former MEDICLIN Herzzentrum Coswig.

In the other activities segment, sales of the nursing care business area (EUR 17.5 mill.) improved by 1.8 % compared with the same period of the previous year. In the prior-year period, this figure still included EUR 0.2 mill. in benefits received under the protective shield to manage the COVID-19 pandemic.

The raw materials and consumables used by the post-acute segment showed a EUR 6.2 mill. increase on the previous year. This is partly due to cost increases amounting to EUR 6.5 mill. with regard to purchased services. The increase refers, on the one hand, to energy costs (EUR +1.3 mill.) and, on the other, to price and occupancy-related cost increases with regard to catering (EUR +1.3 mill.), maintenance cleaning (EUR +1.8 mill.) and a reclassification of costs for building services (EUR 4.1 mill.). The cost of external medical staff decreased by EUR 2.0 mill., while staff costs rose by EUR 8.1 mill. or 4.5 %, respectively.

The acute segment, in turn, posted a decline in the cost of materials and staff. The expenses for raw materials and consumables used dropped by a total of EUR 7.4 mill. or 12.8 % on the prior-year period as expenses for implants (EUR –2.1 mill.) and medical supplies (EUR –2.6 mill.) decreased. The cost of external medical staff decreased by EUR 2.1 mill. The drop in staff costs is primarily attributable to the sale of the former MEDICLIN Herzzentrum Coswig (EUR 10.0 mill. or 8.6 % respectively).

The operating result in the post-acute segment climbed by EUR 2.9 mill. or 8.2 % since the prior-year period, now amounting to EUR 38.0 mill. In the acute segment, the operating result improved by EUR 1.6 mill. (29.6 %) on the back of the aforementioned cost decreases, now amounting to EUR –3.8 mill.

The result in the other activities and reconciliation segment amounts to EUR 0.3 mill. having increased by EUR 0.6 mill.

SALES

In millions of €	9M 2024	9M 2023	Change in %
Post-acute	361.2	337.0	+7.2
Acute	175.5	191.8	–8.5
Other activities and reconciliation	21.5	18.3	+17.5
Thereof nursing care business area	17.5	15.8	+11.3
Group	**558.2**	**547.1**	**+2.0**

RAW MATERIALS AND CONSUMABLES USED

	9M 2024	9M 2023	Change in %
Post-acute			
Raw materials and consumables used in millions of €	73.8	67.6	+9.1
Cost of materials ratio in %	20.4	20.1	
Acute			
Raw materials and consumables used in millions of €	50.0	57.3	–12.8
Cost of materials ratio in %	28.5	29.9	

STAFF COSTS

	9M 2024	9M 2023	Change in %
Post-acute			
Staff costs in millions of €	187.4	179.3	+4.5
Staff costs ratio in %	51.9	53.2	
Acute			
Staff costs in millions of €	106.1	116.1	–8.6
Staff costs ratio in %	60.4	60.5	

SEGMENT RESULT

In millions of €	9M 2024	9M 2023
Post-acute	38.0	35.1
Acute	–3.8	–5.4
Other activities and reconciliation	0.3	–0.3
Group	**34.5**	**29.4**

Employees

The average number of full-time employees decreased to 132 since the prior-year period. All in all, an average of 6,882 employees (9M 2023: 7,014) worked for the Group in the first nine months of the current financial year.

AVERAGE NUMBER OF EMPLOYEES IN THE GROUP AND IN THE SEGMENTS

Shown in full-time employees	9M 2024	9M 2023	Change
Post-acute	3,589	3,643	–54
Acute	1,785	2,022	–237
Other activities	1,508	1,349	+159
Thereof nursing care business area	206	201	+5
Thereof service business area (including administration)	1,302	1,148	+154
Group	**6,882**	**7,014**	**–132**

Forward-looking statements

This report contains forward-looking statements that are based on management's current expectations. Words such as "anticipate", "assume", "believe", "estimate", "expect", "intend", "can/could", "may", "might", "plan", "project", "should" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties that are based on the current assumptions and forecasts of MEDICLIN AG's management. Should any of these risks and uncertainties materialise, or if the assumptions underlying any of the forward-looking statements prove incorrect, then the actual results may be materially different from those expressed or implied by such statements. MEDICLIN AG does not intend or assume any obligation to continuously update these forward-looking statements, so as to adapt them to events or developments that occur after the release of this interim report.

Consolidated interim financial statements of MEDICLIN Aktiengesellschaft

for the period from 1 January 2024 to 30 September 2024

Consolidated interim balance sheet as of 30 September 2024

ASSETS

in €	30.09.2024	31.12.2023
NON-CURRENT ASSETS		
Goodwill and other intangible assets		
Concessions, licences	4,028,841	5,225,985
Goodwill	16,255,079	16,685,079
Payments on account	1,838,962	889,063
	22,122,882	**22,800,127**
Property, plant and equipment		
Land, land rights and buildings including buildings on third-party land	104,132,466	107,585,345
Right-of-use assets on land, land rights and buildings incl. buildings on third-party land	333,831,038	340,010,086
Technical equipment and machines	9,228,356	9,665,036
Operating and office equipment	31,370,868	29,899,393
Right-of-use assets on operating and office equipment	2,714,476	1,574,369
Payments on account and assets under construction	36,891,699	25,644,030
	518,168,903	**514,378,259**
Financial assets		
Investment in stock of subsidiaries	58,822	64,822
Reinsurance cover	704,185	714,093
Other financial investments	2,056	2,056
	765,063	**780,971**
Other assets		
Receivables pursuant to hospital financing law	31,895,980	31,686,130
	31,895,980	**31,686,130**
Deferred tax assets	**11,847,624**	**11,029,692**
	584,800,452	**580,675,179**
CURRENT ASSETS		
Inventories	**7,421,497**	**7,296,364**
Trade receivables	**95,021,880**	**81,581,141**
Other financial assets		
Receivables pursuant to Hospital Compensation Act (KHEntgG) / Federal Directive on Nursing Care Rates (BPflV)	53,454,916	44,216,650
Other current financial assets	9,791,484	14,878,855
	63,246,400	**59,095,505**
Other assets		
Prepaid expenses	5,275,496	2,508,503
Receivables pursuant to hospital financial law	18,242,722	12,712,001
	23,518,218	**15,220,504**
Cash and cash equivalents	**129,993,699**	**115,285,902**
Assets held for sale	**92,489**	**21,347,327**
	319,294,183	**299,826,743**
	904,094,635	**880,501,922**

EQUITY AND LIABILITIES

in €	30.09.2024	31.12.2023
EQUITY		
Share of MEDICLIN Group		
Subscribed capital	47,500,000	47,500,000
Capital reserve	129,391,829	129,391,829
Revenue reserve	36,786,461	35,393,431
Consolidated balance sheet result	–1,471,033	–16,367,284
	212,207,257	**195,917,976**
Non-controlling interests	**180,013**	**111,421**
	212,387,270	**196,029,397**
NON-CURRENT LIABILITIES		
Financial liabilities		
Liabilities to banks	65,429,539	66,418,822
	65,429,539	**66,418,822**
Lease liabilities	**358,918,495**	**362,443,444**
Pensions and similar commitments	**41,045,576**	**41,731,051**
Other provisions	**2,203,023**	**2,233,213**
Other payables		
Liabilities pursuant to hospital financing law	38,642,476	38,899,462
Miscellaneous payables	1,618,766	1,507,473
	40,261,242	**40,406,935**
	507,857,875	**513,233,465**
CURRENT LIABILITIES		
Trade payables	**9,539,889**	**12,626,311**
Financial liabilities		
Liabilities to banks	26,600,793	26,962,376
	26,600,793	**26,962,376**
Lease liabilities	**26,037,515**	**23,999,770**
Other provisions	**13,236,924**	**12,338,610**
Current income tax liabilities	**5,650,929**	**3,540,964**
Other financial liabilities		
Liabilities pursuant to Hospital Compensation Act (KHEntgG) / Federal Directive on Nursing Care Rates (BPflV)	8,069,495	9,224,395
Miscellaneous financial liabilities	8,505,827	7,799,064
	16,575,322	**17,023,459**
Other payables		
Liabilities pursuant to hospital financing law	34,208,113	25,253,809
Miscellaneous payables	52,000,005	43,277,851
	86,208,118	**68,531,660**
Liabilities in connection with assets held for sale	**0**	**6,215,910**
	183,849,490	**171,239,060**
	904,094,635	**880,501,922**

Consolidated interim profit and loss account

in €	Jan. – Sept. 2024	Jan. – Sept. 2023
Sales	558,220,404	547,135,857
Other operating income	15,429,606	22,162,013
Total operating performance	**573,650,010**	**569,297,870**
Raw materials and consumables used		
a) Cost of raw materials and supplies	–58,494,466	–62,533,751
b) Cost of purchased services	–38,038,683	–41,782,380
	–96,533,149	**–104,316,131**
Staff costs		
a) Wages and salaries	–298,338,934	–292,873,288
b) Social security, pension and retirement	–55,331,328	–54,323,497
	–353,670,262	**–347,196,785**
Other operating expenses	–51,829,733	–49,539,377
Result before interest, taxes, depreciation and amortisation / EBITDA	**71,616,866**	**68,245,577**
Depreciation and amortisation	–37,149,549	–38,860,782
Operating result / EBIT	**34,467,317**	**29,384,795**
Financial result		
a) Income from participations	0	0
b) Interest and similar income	2,034,670	1,898,693
c) Interest and similar expenses	–18,087,030	–17,842,761
	–16,052,360	**–15,944,068**
Result before tax	**18,414,957**	**13,440,727**
Taxes on income	–3,462,028	1,787,248
Total consolidated result	**14,952,929**	**15,227,975**
Thereof attributable to shareholders of MEDICLIN AG	14,896,251	15,273,913
Thereof attributable to non-controlling interests	56,678	–45,938
Total consolidated result attributable to shareholders of MEDICLIN AG per share		
Undiluted in €	0.31	0.32
Diluted in €	0.31	0.32

Consolidated interim statement of comprehensive income

in €	Jan. – Sept. 2024	Jan. – Sept. 2023
Total consolidated result	**14,952,929**	**15,227,975**
Other comprehensive income		
Revaluation from defined benefit plans and similar obligations	1,669,075	2,093,461
Taxes on income	–264,131	–331,290
Additions to value adjustments that are not reconciled to the total consolidated result	**1,404,944**	**1,762,171**
Thereof attributable to shareholders of MEDICLIN AG	1,393,030	1,748,172
Thereof attributable to non-controlling interests	11,914	13,999
Additions to value adjustments that are reconciled to the total consolidated result	**0**	**0**
Group comprehensive income	**16,357,873**	**16,990,146**
Thereof attributable to shareholders of MEDICLIN AG	16,289,281	17,022,085
Thereof attributable to non-controlling interests	68,592	–31,939

Consolidated cash flow statement

in €	Jan. – Sept. 2024	Jan. – Sept. 2023
Total consolidated result	**14,952,929**	**15,227,975**
Result of finance activities	16,052,360	15,944,068
Result of income taxes	3,462,028	–1,787,248
Operating result (EBIT)	**34,467,317**	**29,384,795**
Depreciation on fixed asset items	37,149,549	38,860,782
Result before interest, taxes, depreciation and amortisation (EBITDA)	**71,616,866**	**68,245,577**
Change in non-current provisions	–127,131	–1,318,553
Change in current provisions	–491,785	234,394
Result from the disposal of fixed asset items	–210,911	–34,521
Result from other non-cash items	–2,007,170	–6,021,525
Change in other current assets	–11,309,300	–14,718,277
Change in other non-current liabilities	31,219	40,645
Change in other current liabilities	2,284,683	–1,721,714
Payments received from interest	2,034,670	1,898,693
Income taxes paid	–2,287,191	3,253,741
Cash flow from operating activities	**59,533,950**	**49,858,460**
Payments received from the disposal of fixed assets	**783,190**	**108,619**
From the disposal of property, plant and equipment	783,190	108,619
Payments received from investment subsidies	**11,374,138**	**17,791,077**
Cash used for investments	**–30,190,602**	**–24,897,631**
For intangible assets	–2,537,466	–2,303,604
For property, plant and equipment	–27,653,136	–22,594,027
Proceeds from divestments	9,500,000	9,500,000
Cash flow from investing activities	**–8,533,274**	**2,502,065**
Repayment of lease liabilities	–17,901,493	–16,477,585
Repayment of financial liabilities	–959,965	–1,236,818
Interest payments for lease liabilities	–14,062,595	–14,368,951
Other interest payments	–3,371,604	–2,060,990
Cash flow from financing activities	**–36,295,657**	**–34,144,344**
Change in consolidation scopes for financial funds	0	–851,705
Cash flow for the period	**14,705,019**	**17,364,476**
Cash and cash equivalents at the beginning of the period	115,288,680	92,277,469
Cash and cash equivalents at the end of the period	**129,993,699**	**109,641,945**

Statement of changes in equity

in €	Subscribed capital	Capital reserve	Revenue reserve	Consolidated balance sheet result	Shares MEDICLIN Group	Non-controlling interests	Total equity
As of 01.01.2023	47,500,000	129,391,829	37,906,157	–5,591,162	209,206,824	115,976	209,322,800
Total consolidated result	–	–	–	15,273,913	15,273,913	–45,938	15,227,975
Other compre-hensive income	–	–	1,748,172	–	1,748,172	13,999	1,762,171
Group compre-hensive income	**–**	**–**	**1,748,172**	**15,273,913**	**17,022,085**	**–31,939**	**16,990,146**
As of 30.09.2023	**47,500,000**	**129,391,829**	**39,654,329**	**9,682,751**	**226,228,909**	**84,037**	**226,312,946**

in €	Subscribed capital	Capital reserve	Revenue reserve	Consolidated balance sheet result	Shares MEDICLIN Group	Non-controlling interests	Total equity
As of 01.01.2024	47,500,000	129,391,829	35,393,431	–16,367,284	195,917,976	111,421	196,029,397
Total consolidated result	–	–	–	14,896,251	14,896,251	56,678	14,952,929
Other compre-hensive income	–	–	1,393,030	–	1,393,030	11,914	1,404,944
Group compre-hensive income	**–**	**–**	**1,393,030**	**14,896,251**	**16,289,281**	**68,592**	**16,357,873**
Stand 30.09.2024	**47,500,000**	**129,391,829**	**36,786,461**	**–1,471,033**	**212,207,257**	**180,013**	**212,387,270**

Notes

General Information

The unaudited consolidated interim financial statements of MEDICLIN for the first nine months of the 2024 financial year were prepared in accordance with International Accounting Standard 34. The same accounting policies as used in the consolidated financial statements for the 2023 financial year were also applied in this interim report. The interim report should therefore be read in conjunction with the Company’s 2023 annual report and the interim reports for the first quarter and the first half-year of 2024.

The discount rate for pension provisions pursuant to IAS 19 amounted to 3.5 % on 30 September 2024 (30.06.2024: 3.6 %; 31.03.2024: 3.4 %, 31.12.2023: 3.2 %).

Quarterly development in the Group

In millions of €	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Sales	182.3	188.1	176.7	178.4	171.0	181.1	174.2
EBITDA	31.2	25.7	11.3	25.7	22.6	27.0	15.6
EBITDA margin in %	17.1	13.7	6.4	14.4	13.2	14.9	8.9
EBIT (operating result)	18.1	13.0	–1.7	9.4	3.5	9.2	–2.6
EBITDA margin in %	9.9	6.9	–0.9	5.3	2.1	5.1	–1.5
Financial result	–5.6	–4.4	–5.9	–3.9	–1.7	–2.0	–2.1
Total consolidated result	10.5	11.0	–6.3	5.3	2.1	6.2	–3.9
Earnings per share in €	0.22	0.23	–0.13	0.11	0.04	0.13	–0.08
Cash flow from operating activities	27.4	4.9	17.6	0.1	25.6	–4.6	13.5
Cash flow from operating activities per share in €	0.58	0.10	0.37	0.01	0.54	–0.10	0.28
Equity ratio in %	24.8	23.6	22.2	22.8	24.5	23.7	21.0
Gross capital expenditure (without right-of-use assets pursuant to IFRS 16)	9.3	8.6	8.1	10.9	8.1	5.7	3.8
Net finacial debt[1] (end of quarter)	8.1	28.4	32.6	34.2	25.3	29.4	34.4
Number of beds (inpatient)	27,560	26,911	26,513	26,321	26,811	26,632	25,052
Number of cases (end of quarter)	8,132	8,132	8,172	8,315	8,315	8,325	8,311
Occupancy rates in %	86.2	84.8	82.4	76.4	79.4	79.6	76.5
Number of full-time employees (quarterly average)	6,960	7,022	7,061	7,059	7,051	6,988	7,003

1 Adjusted net financial debt

Key data on the MEDICLIN SHARE

ISIN: DE 000659 5101; WKN: 659 510; TICKER: MED

In € per share	9M 2024	9M 2023
Earnings, undiluted / diluted	0.31	0.32
Cash flow from operating activities	1.25	1.05
Book value[1] as of 30.09.	4.47	4.76
Share price as of 30.09.	2.36	2.78
52-weeks high	3.00	–
52-weeks low	2.28	–
Market capitalisation as of 30.09. in millions of €	112.1	132.1
Number of shares in millions	47.5	47.5

[1] Equity less non-controlling interests

Source: Deutsche Börse AG; Xetra / as of 09.10.2024

Financial calendar

27 February 2025
Disclosure of the preliminary figures for the 2024 financial year

28 March 2025
Annual press and analysts' conference for the 2024 financial year

2 May 2025
Publication of the interim report from 1 January 2025 to 31 March 2025

4 June 2025
Annual General Meeting

31 July 2025
Publication of the interim report from 1 January 2025 to 30 June 2025

4 November 2025
Publication of the interim report from 1 January 2025 to 30 September 2025

Adresses and imprint

MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg
Telefon +49 (0) 7 81 / 4 88-0
Telefax +49 (0) 7 81 / 4 88-133
E-Mail info@mediclin.de
www.mediclin.de

Investor Relations
Ender Gülcan
Telefon +49 (0) 7 81 / 4 88-326
E-Mail ender.guelcan@mediclin.de

Kontakt für Medienanfragen
Unternehmenskommunikation
Dr. Janina Lossen
Telefon +49 (0) 7 81 / 4 88-0
E-Mail janina.lossen@mediclin.de

This interim report is also available in German.

This is a translation of the German Interim Report.

In case of divergence from the German version, the German version shall prevail.

www.mediclin.de

Prevention | Acute care | Post-acute care | Nursing care